市場調査レポート
商品コード
1463668

北米の放射性医薬品セラノスティクス:2028年までの市場予測 - 地域分析 - 製品タイプ、ラジオアイソトープ、供給源、用途、適応症、エンドユーザー別

North America Radiopharmaceutical Theranostics Market Forecast to 2028 - Regional Analysis - by Product Type, Radioisotope, Source, Application, Indication, and End User

出版日: | 発行: The Insight Partners | ページ情報: 英文 185 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.89円
北米の放射性医薬品セラノスティクス:2028年までの市場予測 - 地域分析 - 製品タイプ、ラジオアイソトープ、供給源、用途、適応症、エンドユーザー別
出版日: 2024年02月08日
発行: The Insight Partners
ページ情報: 英文 185 Pages
納期: 即納可能 即納可能とは
  • 全表示
  • 概要
  • 図表
  • 目次
概要

北米の放射性医薬品セラノスティクス市場は、2022年に7億9,588万米ドルと評価され、2028年には15億2,995万米ドルに達すると予測され、2022年から2028年までのCAGRは11.5%と推定されます。

心血管疾患の治療における用途の増加

心血管疾患(CVDs)は、21世紀において最も蔓延している慢性疾患のひとつであり、死亡率も高いです。座りがちなライフスタイルのため、CVDは先進国における死亡率および罹患率の主な原因となっています。また、肥満や糖尿病、その関連疾患は心血管疾患と関連し、併存しつつあります。さらに、冠動脈閉塞のような合併症は、成人の死亡原因の第1位であり、主に頸動脈の動脈壁内膜に血栓プラークが生じる。心血管疾患における治療応用には、狭心症、心筋炎、心筋梗塞、心膜疾患、血栓症、アテローム性動脈硬化症、高脂血症、高血圧、肺動脈性肺高血圧症、脳卒中におけるナノメディシンが含まれます。セラノスティック・ナノメディシンは、全身循環を延長し、宿主の防御システムを回避し、セラノスティック薬剤を標的部位に送達して、細胞・分子レベルでのイメージングや治療を行うことができます。

米国疾病予防管理センター(CDC)の2022年の報告によると、心臓病は米国の男女の死亡原因の第1位です。心臓病は、2020年に米国で~697,000人、i.5人に1人が死亡する原因でした。米国国立衛生研究所の報告書によると、CVDに関連する複雑な病態生理学的合併症を克服するのに役立つ技術として、セラノスティック・ナノ粒子が医療分野で大きな注目を集めています。アテローム性動脈硬化症患者の心血管イメージングは、CVDの治療に役立つ病態生理学的証拠を提供します。さらに、セラノスティック・ナノ粒子は、磁気共鳴画像法、陽電子放射断層撮影法(PET)、コンピュータ断層撮影法(CT)など、さまざまな画像診断技術と組み合わせることができます。これまでに臨床研究所でさまざまな臨床研究が行われてきました。高分子光音響プローブとナノ粒子-PLCDP@PMHを組み合わせた3-in-one治療複合体を構築しました。PLCDP@PMHは、患者の早期アテローム性動脈硬化症検出のためのセラノスティクス・アプローチに有利な利点をもたらすことが、臨床in-vivo評価で明らかになった。

北米の放射性医薬品セラノスティクス市場概要

北米の放射性医薬品セラノスティクス市場は、米国、カナダ、メキシコに区分されます。米国は放射性医薬品セラノスティクス市場において最大の貢献国のひとつとなる見込みです。同地域の発展は、慢性疾患の増加、政府による支援策の存在、市場参入企業による戦略的イニシアチブの拡大、革新的な放射線治療の開発などによるものです。

北米の放射性医薬品セラノスティクス市場の収益と2028年までの予測(金額)

北米の放射性医薬品セラノスティクス市場セグメンテーション

北米の放射性医薬品セラノスティクス市場は、製品タイプ、放射性同位元素、線源、用途、適応症、エンドユーザー、国に区分されます。製品タイプに基づき、北米の放射性医薬品セラノスティクス市場はアルファ線放出核種、ベータ線放出核種、陽電子放出断層撮影(PET)トレーサーに区分されます。PETトレーサーセグメントが2022年に最大の市場シェアを占めました。

放射性同位元素に基づいて、北米の放射性医薬品セラノスティクス市場はテクネチウム-99、ガリウム-68、ヨウ素-131、ヨウ素-123、フッ素-18(18F)、イットリウム90(Y-90)、ルテチウム(Lu)177、銅(Cu)67、銅(Cu)64、その他に区分されます。ルテチウム(Lu)177セグメントが2022年に最大の市場シェアを占めました。

線源に基づき、北米の放射性医薬品セラノスティクス市場は原子炉とサイクロトロンに二分されます。サイクロトロンセグメントが2022年に大きな市場シェアを占めました。

用途別では、北米の放射性医薬品セラノスティクス市場は標的治療(Rx)とコンパニオン診断(CDx)に二分されます。2022年には、標的治療(Rx)分野がより大きな市場シェアを占めています。

適応症に基づき、北米の放射性医薬品セラノスティクス市場は腫瘍学、循環器学、神経学、その他に区分されます。2022年には腫瘍分野が最大の市場シェアを占めました。

エンドユーザー別に見ると、北米の放射性医薬品セラノスティクス市場は、病院、画像診断センター、学術・研究機関、その他に区分されます。2022年には腫瘍分野が最大の市場シェアを占めました。

国別では、北米の放射性医薬品セラノスティクス市場は米国、カナダ、メキシコに区分されます。2022年の北米の放射性医薬品セラノスティクス市場シェアは米国が独占しました。

Bayer AG;GE Healthcare Technologies Inc.;Curium;Lantheus Medical Imaging, Inc.;Telix Pharmaceuticals Ltd.;Cardinal Health Inc.;Advanced Accelerator Applications S.A;Jubilant Radiopharma;Theragnostics;and NuView Life Sciencesが北米の放射性医薬品セラノスティクス市場で事業を展開する主要企業です。

目次

第1章 イントロダクション

第2章 放射性医薬品セラノスティクス市場-主要な要点

第3章 調査手法

  • 調査範囲
  • 2次調査
  • 1次調査

第4章 北米の放射性医薬品セラノスティクス市場:市場情勢

  • PEST分析
    • 北米のPEST分析
  • 専門家の見解

第5章 北米の放射性医薬品セラノスティクス市場:主要市場力学

  • 市場促進要因
    • がん罹患率の上昇
    • 心血管疾患治療への応用拡大
  • 市場抑制要因
    • 放射性医薬品セラノスティクスの承認に向けた規制課題
  • 市場機会
    • 個別化放射性医薬品治療のためのセラノスティック・デジタルツイン
  • 今後の動向
    • 核医学における放射性医薬品セラノスティクス
  • 影響分析

第6章 放射性医薬品セラノスティクス市場:北米分析

  • 北米の放射性医薬品セラノスティクス市場収益と予測分析

第7章 北米の放射性医薬品セラノスティクス市場:収益と2028年までの予測 - 製品タイプ別

  • 市場収益シェア(2021年・2028年)

第8章 北米の放射性医薬品セラノスティクス市場分析 - ラジオアイソトープ別

  • 市場収益シェア(2021年・2028年)

第9章 北米の放射性医薬品セラノスティクスの市場分析 - 供給源別

  • 市場収益シェア(2021年・2028年)

第10章 北米の放射性医薬品セラノスティクス市場の分析 - 用途別

  • 市場収益シェア(2021年・2028年)

第11章 北米の放射性医薬品セラノスティクス市場の分析 - 適応症別

  • 市場収益シェア(2021年・2028年)

第12章 北米の放射性医薬品セラノスティクス市場の分析 - エンドユーザー別

  • 市場収益シェア(2021年・2028年)

第13章 北米の放射性医薬品セラノスティクス市場:収益と2028年までの予測:国別分析

  • 北米
    • 米国
    • カナダ
    • メキシコ

第14章 放射性医薬品セラノスティクス市場- 業界情勢

  • 放射性医薬品セラノスティクス市場における成長戦略
  • 無機的成長戦略
  • 有機的成長戦略

第15章 企業プロファイル

  • Bayer AG
  • GE HealthCare Technologies Inc
  • Curium
  • Lantheus Medical Imaging, Inc.
  • Telix Pharmaceuticals Ltd.
  • Cardinal Health Inc
  • Advanced Accelerator Applications S.A.
  • Jubilant Radiopharma
  • Theragnostics
  • NuView Life Sciences

第16章 付録

図表

List Of Tables

  • Table 1. United States Radiopharmaceutical Theranostics Market, by Product Type - Revenue and Forecast to 2028 (US$ Million)
  • Table 2. United States Radiopharmaceutical Theranostics Market, by Radioisotope - Revenue and Forecast to 2028 (US$ Million)
  • Table 3. United States Radiopharmaceutical Theranostics Market, by Source - Revenue and Forecast to 2028 (US$ Million)
  • Table 4. United States Radiopharmaceutical Theranostics Market, by Application - Revenue and Forecast to 2028 (US$ Million)
  • Table 5. United States Radiopharmaceutical Theranostics Market, by Indication - Revenue and Forecast to 2028 (US$ Million)
  • Table 6. United States Radiopharmaceutical Theranostics Market, by End User - Revenue and Forecast to 2028 (US$ Million)
  • Table 7. Canada Radiopharmaceutical Theranostics Market, by Product Type - Revenue and Forecast to 2028 (US$ Million)
  • Table 8. Canada Radiopharmaceutical Theranostics Market, by Radioisotope - Revenue and Forecast to 2028 (US$ Million)
  • Table 9. Canada Radiopharmaceutical Theranostics Market, by Source - Revenue and Forecast to 2028 (US$ Million)
  • Table 10. Canada Radiopharmaceutical Theranostics Market, by Application - Revenue and Forecast to 2028 (US$ Million)
  • Table 11. Canada Radiopharmaceutical Theranostics Market, by Indication - Revenue and Forecast to 2028 (US$ Million)
  • Table 12. Canada Radiopharmaceutical Theranostics Market, by End User - Revenue and Forecast to 2028 (US$ Million)
  • Table 13. Mexico Radiopharmaceutical Theranostics Market, by Product Type - Revenue and Forecast to 2028 (US$ Million)
  • Table 14. Mexico Radiopharmaceutical Theranostics Market, by Radioisotope - Revenue and Forecast to 2028 (US$ Million)
  • Table 15. Mexico Radiopharmaceutical Theranostics Market, by Source - Revenue and Forecast to 2028 (US$ Million)
  • Table 16. Mexico Radiopharmaceutical Theranostics Market, by Application - Revenue and Forecast to 2028 (US$ Million)
  • Table 17. Mexico Radiopharmaceutical Theranostics Market, by Indication - Revenue and Forecast to 2028 (US$ Million)
  • Table 18. Mexico Radiopharmaceutical Theranostics Market, by End User - Revenue and Forecast to 2028 (US$ Million)
  • Table 19. Recent Inorganic Growth Strategies in the Radiopharmaceutical Theranostics Market
  • Table 20. Recent Organic Growth Strategies in the Radiopharmaceutical Theranostics Market
  • Table 21. Glossary of Terms

List Of Figures

  • Figure 1. North America Radiopharmaceutical Theranostics Market Segmentation
  • Figure 2. North America Radiopharmaceutical Theranostics Market, by Country
  • Figure 3. North America Radiopharmaceutical Theranostics Market Overview
  • Figure 4. Positron Emission Tomography (PET) Tracers Segment Held Largest Share of Product Type Segment in Radiopharmaceutical Theranostics Market
  • Figure 5. US Expected to Show Remarkable Growth During Forecast Period
  • Figure 6. North America: PEST Analysis
  • Figure 7. North America Experts' Opinion
  • Figure 8. North America Radiopharmaceutical Theranostics Market: Impact Analysis of Drivers and Restraints
  • Figure 9. North America Radiopharmaceutical Theranostics Market - Revenue Forecast and Analysis - 2020-2028
  • Figure 10. North America Radiopharmaceutical Theranostics Market Revenue Share, by Product Type 2021 & 2028 (%)
  • Figure 11. Positron Emission Tomography (PET) Tracers: North America Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 12. Beta Emitters: North America Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 13. Alpha Emitters: North America Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 14. North America Radiopharmaceutical Theranostics Market, by Radioisotope, 2021 & 2028 (%)
  • Figure 15. Technetium-99: North America Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 16. Gallium-68: North America Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 17. Iodine-131: North America Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 18. Iodine-123: North America Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 19. Fluorine-18 (18F): North America Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 20. Yttrium 90 (Y-90): North America Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 21. Lutetium (LU) 177: North America Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 22. Copper (CU) 67: North America Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 23. Copper (CU) 64: North America Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 24. Others: North America Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 25. North America Radiopharmaceutical Theranostics Market, by Source, 2021 & 2028 (%)
  • Figure 26. Nuclear Reactors: North America Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 27. Cyclotrons: North America Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 28. North America Radiopharmaceutical Theranostics Market, by Application, 2021 & 2028 (%)
  • Figure 29. Targeted Therapeutics (Rx): North America Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 30. Companion Diagnostics (CDx): North America Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 31. North America Radiopharmaceutical Theranostics Market, by Indication, 2021 & 2028 (%)
  • Figure 32. Oncology: North America Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 33. Neurology: North America Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 34. Cardiology: North America Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 35. Others: North America Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 36. North America Radiopharmaceutical Theranostics Market, by End User, 2021 & 2028 (%)
  • Figure 37. Hospitals: North America Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 38. Diagnostic Imaging Centers: North America Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 39. Academic & Research Institutes: North America Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 40. Others: North America Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 41. North America: Radiopharmaceutical Theranostics Market, by Key Country - Revenue (2021) (US$ Million)
  • Figure 42. North America: Radiopharmaceutical Theranostics Market, by Country, 2021 & 2028 (%)
  • Figure 43. United States: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 44. Canada: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 45. Mexico: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 46. Growth Strategies in the Radiopharmaceutical Theranostics Market
目次
Product Code: BMIRE00028187

The North America radiopharmaceutical theranostics market was valued at US$ 795.88 million in 2022 and is expected to reach US$ 1,529.95 million by 2028; it is estimated to register a CAGR of 11.5% from 2022 to 2028.

Rising Application in Treatment of Cardiovascular Disorders

Cardiovascular diseases (CVDs) are among the most prevalent chronic diseases of the 21st century, with a high mortality rate. Due to their sedentary lifestyle, CVDs are the leading cause of mortality and morbidity in developed countries. In addition, obesity and diabetes, and related diseases are associated with cardiovascular disease and are becoming comorbid. In addition, a complication such as coronary artery obstruction is one of the number one causes of death in adults, resulting in thrombus plaque in the intima of the arterial wall, mainly in the carotid artery. Therapeutic applications in cardiovascular diseases include nanomedicine in angina pectoris, myocarditis, myocardial infarction, pericardial disease, thrombosis, atherosclerosis, hyperlipidemia, hypertension, pulmonary arterial hypertension, and stroke. Theranostic nanomedicines can prolong systemic circulation, evade host defense systems, and deliver theranostic agents to the target site for imaging and therapy at the cellular and molecular levels.

As per the 2022 report by the Centers for Disease Control and Prevention (CDC), heart disease is a leading cause of death among men and women in the US. Heart disease was a cause of ~697,000 deaths, i.e., 1 in 5 deaths, in the US in 2020. A National Institute of Health report states that theranostic nanoparticles have gained significant attention in the medical field, as the techniques help overcome complexities and pathophysiological complications associated with CVDs. Cardiovascular imaging of atherosclerosis patients provides pathophysiological evidence that can help treat CVDs. Further, theranostic nanoparticles can be combined with a range of imaging techniques, such as magnetic resonance imaging, positron emission tomography (PET), and computed tomography (CT). Various clinical research studies have been conducted in clinical laboratories so far. A three-in-one therapeutic complex has been constructed, by combining a polymeric photoacoustic probe with nanoparticles-PLCDP@PMH. Clinical in-vivo evaluations reveal that the PLCDP@PMH provides lucrative advantages for the theranostics approach to early-stage atherosclerosis detection in patients.

North America Radiopharmaceutical Theranostics Market Overview

The North America radiopharmaceutical theranostics market is segmented into US, Canada, and Mexico. The US is expected to be among the largest contributors to the radiopharmaceutical theranostics market. The market growth in this region is due to the increasing incidences of chronic diseases, presence of supportive government plans, growing strategic initiatives by the market players, and development of innovative radiotherapies.

North America Radiopharmaceutical Theranostics Market Revenue and Forecast to 2028 (US$ Million)

North America Radiopharmaceutical Theranostics Market Segmentation

The North America radiopharmaceutical theranostics market is segmented into product type, radioisotope, source, application, indication, end user, and country. Based on product type, the North America radiopharmaceutical theranostics market is segmented into alpha emitters, beta emitters, and Positron Emission Tomography (PET) tracers. The PET tracers segment held the largest market share in 2022.

Based on radioisotope, the North America radiopharmaceutical theranostics market is segmented into technetium-99, gallium-68, iodine-131, iodine-123, Fluorine-18 (18F), Yttrium 90 (Y-90), Lutetium (Lu) 177, Copper (Cu) 67, Copper (Cu) 64, and others. The Lutetium (Lu) 177 segment held the largest market share in 2022.

Based on source, the North America radiopharmaceutical theranostics market is bifurcated into nuclear reactors and cyclotrons. The cyclotrons segment held a larger market share in 2022.

Based on application, the North America radiopharmaceutical theranostics market is bifurcated into targeted therapeutic (Rx) and Companion Diagnostic (CDx). The targeted therapeutic (Rx) segment held a larger market share in 2022.

Based on indication, the North America radiopharmaceutical theranostics market is segmented into oncology, cardiology, neurology, and others. The oncology segment held the largest market share in 2022.

Based on end user, the North America radiopharmaceutical theranostics market is segmented into hospitals, diagnostic imaging centers, academic and research institutes, and others. The oncology segment held the largest market share in 2022.

Based on country, the North America radiopharmaceutical theranostics market is segmented into the US, Canada, and Mexico. The US dominated the North America radiopharmaceutical theranostics market share in 2022.

Bayer AG; GE Healthcare Technologies Inc.; Curium; Lantheus Medical Imaging, Inc.; Telix Pharmaceuticals Ltd.; Cardinal Health Inc.; Advanced Accelerator Applications S.A; Jubilant Radiopharma; Theragnostics; and NuView Life Sciences are the leading companies operating in the North America radiopharmaceutical theranostics market.

Table Of Contents

1. Introduction

  • 1.1 Scope of the Study
  • 1.2 The Insight Partners Research Report Guidance
  • 1.3 Market Segmentation
    • 1.3.1 North America Radiopharmaceutical Theranostics Market - by Product Type
    • 1.3.2 North America Radiopharmaceutical Theranostics Market - by Radioisotope
    • 1.3.3 North America Radiopharmaceutical Theranostics Market - by Source
    • 1.3.4 North America Radiopharmaceutical Theranostics Market - by Application
    • 1.3.5 North America Radiopharmaceutical Theranostics Market - by Indication
    • 1.3.6 North America Radiopharmaceutical Theranostics Market - by End User
    • 1.3.7 North America Radiopharmaceutical Theranostics Market - by Country

2. Radiopharmaceutical Theranostics Market - Key Takeaways

3. Research Methodology

  • 3.1 Coverage
  • 3.2 Secondary Research
  • 3.3 Primary Research

4. North America Radiopharmaceutical Theranostics Market - Market Landscape

  • 4.1 Overview
  • 4.2 PEST Analysis
    • 4.2.1 North America PEST Analysis
  • 4.3 Expert's Opinion

5. North America Radiopharmaceutical Theranostics Market - Key Market Dynamics

  • 5.1 Market Drivers
    • 5.1.1 Rising Incidence of Cancer
    • 5.1.2 Rising Application in Treatment of Cardiovascular Disorders
  • 5.2 Market Restraints
    • 5.2.1 Regulatory Challenges for Approval of Radiopharmaceutical Theranostics
  • 5.3 Market Opportunities
    • 5.3.1 Theranostic Digital Twins for Personalized Radiopharmaceutical Therapies
  • 5.4 Future Trends
    • 5.4.1 Radiopharmaceutical Theranostics in Nuclear Medicine
  • 5.5 Impact Analysis

6. Radiopharmaceutical Theranostics Market - North America Analysis

  • 6.1 North America Radiopharmaceutical Theranostics Market Revenue Forecast and Analysis

7. North America Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 - by Product Type

  • 7.1 Overview
  • 7.2 Radiopharmaceutical Theranostics Market Revenue Share, by Product Type 2021 & 2028 (%)
    • 7.2.1 Positron Emission Tomography (PET) Tracers
      • 7.2.1.1 Overview
      • 7.2.1.2 Positron Emission Tomography (PET) Tracers: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
    • 7.2.2 Beta Emitters
      • 7.2.2.1 Overview
      • 7.2.2.2 Beta Emitters: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
    • 7.2.3 Alpha Emitters
      • 7.2.3.1 Overview
      • 7.2.3.2 Alpha Emitters: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)

8. North America Radiopharmaceutical Theranostics Market Analysis - by Radioisotope

  • 8.1 Overview
  • 8.2 Radiopharmaceutical Theranostics Market Revenue Share, by Radioisotope 2021 & 2028 (%)
    • 8.2.1 Technetium-99
      • 8.2.1.1 Overview
      • 8.2.1.2 Technetium-99: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
    • 8.2.2 Gallium-68
      • 8.2.2.1 Overview
      • 8.2.2.2 Gallium-68: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
    • 8.2.3 Iodine-131
      • 8.2.3.1 Overview
      • 8.2.3.2 Iodine-131: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
    • 8.2.4 Iodine-123
      • 8.2.4.1 Overview
      • 8.2.4.2 Iodine-123: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
    • 8.2.5 Fluorine-18 (18F)
      • 8.2.5.1 Overview
      • 8.2.5.2 Fluorine-18 (18F): Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
    • 8.2.6 Yttrium 90 (Y-90)
      • 8.2.6.1 Overview
      • 8.2.6.2 Yttrium 90 (Y-90): Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
    • 8.2.7 Lutetium (LU) 177
      • 8.2.7.1 Overview
      • 8.2.7.2 Lutetium (LU) 177: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
    • 8.2.8 Copper (CU) 67
      • 8.2.8.1 Overview
      • 8.2.8.2 Copper (CU) 67: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
    • 8.2.9 Copper (CU) 64
      • 8.2.9.1 Overview
      • 8.2.9.2 Copper (CU) 64: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
    • 8.2.10 Others
      • 8.2.10.1 Overview
      • 8.2.10.2 Others: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)

9. North America Radiopharmaceutical Theranostics Market Analysis - by Source

  • 9.1 Overview
  • 9.2 Radiopharmaceutical Theranostics Market Revenue Share, by Source 2021 & 2028 (%)
    • 9.2.1 Nuclear Reactors
      • 9.2.1.1 Overview
      • 9.2.1.2 Nuclear Reactors: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
    • 9.2.2 Cyclotrons
      • 9.2.2.1 Overview
      • 9.2.2.2 Cyclotrons: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)

10. North America Radiopharmaceutical Theranostics Market Analysis - by Application

  • 10.1 Overview
  • 10.2 Radiopharmaceutical Theranostics Market Revenue Share, by Application 2021 & 2028 (%)
    • 10.2.1 Targeted Therapeutic (Rx)
      • 10.2.1.1 Overview
      • 10.2.1.2 Targeted Therapeutics (Rx): Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
    • 10.2.2 Companion Diagnostic (CDx)
      • 10.2.2.1 Overview
      • 10.2.2.2 Companion Diagnostics (CDx): Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)

11. North America Radiopharmaceutical Theranostics Market Analysis - by Indication

  • 11.1 Overview
  • 11.2 Radiopharmaceutical Theranostics Market Revenue Share, by Indication 2021 & 2028 (%)
    • 11.2.1 Oncology
      • 11.2.1.1 Overview
      • 11.2.1.2 Oncology: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
    • 11.2.2 Neurology
      • 11.2.2.1 Overview
      • 11.2.2.2 Neurology: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
    • 11.2.3 Cardiology
      • 11.2.3.1 Overview
      • 11.2.3.2 Cardiology: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
    • 11.2.4 Others
      • 11.2.4.1 Overview
      • 11.2.4.2 Others: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)

12. North America Radiopharmaceutical Theranostics Market Analysis - by End User

  • 12.1 Overview
  • 12.2 Radiopharmaceutical Theranostics Market Revenue Share, by End User 2021 & 2028 (%)
    • 12.2.1 Hospitals
      • 12.2.1.1 Overview
      • 12.2.1.2 Hospitals: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
    • 12.2.2 Diagnostic Imaging Centers
      • 12.2.2.1 Overview
      • 12.2.2.2 Diagnostic Imaging Centers: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
    • 12.2.3 Academic & Research Institutes
      • 12.2.3.1 Overview
      • 12.2.3.2 Academic & Research Institutes: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
    • 12.2.4 Others
      • 12.2.4.1 Overview
      • 12.2.4.2 Others: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)

13. North America Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 - by Country Analysis

  • 13.1 North America: Radiopharmaceutical Theranostics Market
    • 13.1.1 Overview
      • 13.1.1.1 United States: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
        • 13.1.1.1.1 Overview
        • 13.1.1.1.2 United States: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
        • 13.1.1.1.3 United States Radiopharmaceutical Theranostics Market, by Product Type, 2019-2028 (US$ Million)
        • 13.1.1.1.4 United States Radiopharmaceutical Theranostics Market, by Radioisotope, 2019-2028 (US$ Million)
        • 13.1.1.1.5 United States Radiopharmaceutical Theranostics Market, by Source, 2019-2028 (US$ Million)
        • 13.1.1.1.6 United States Radiopharmaceutical Theranostics Market, by Application, 2019-2028 (US$ Million)
        • 13.1.1.1.7 United States Radiopharmaceutical Theranostics Market, by Indication, 2019-2028 (US$ Million)
        • 13.1.1.1.8 United States Radiopharmaceutical Theranostics Market, by End User, 2019-2028 (US$ Million)
      • 13.1.1.2 Canada: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
        • 13.1.1.2.1 Overview
        • 13.1.1.2.2 Canada: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
        • 13.1.1.2.3 Canada Radiopharmaceutical Theranostics Market, by Product Type, 2019-2028 (US$ Million)
        • 13.1.1.2.4 Canada Radiopharmaceutical Theranostics Market, by Radioisotope, 2019-2028 (US$ Million)
        • 13.1.1.2.5 Canada Radiopharmaceutical Theranostics Market, by Source, 2019-2028 (US$ Million)
        • 13.1.1.2.6 Canada Radiopharmaceutical Theranostics Market, by Application, 2019-2028 (US$ Million)
        • 13.1.1.2.7 Canada Radiopharmaceutical Theranostics Market, by Indication, 2019-2028 (US$ Million)
        • 13.1.1.2.8 Canada Radiopharmaceutical Theranostics Market, by End User, 2019-2028 (US$ Million)
      • 13.1.1.3 Mexico: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
        • 13.1.1.3.1 Overview
        • 13.1.1.3.2 Mexico: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
        • 13.1.1.3.3 Mexico Radiopharmaceutical Theranostics Market, by Product Type, 2019-2028 (US$ Million)
        • 13.1.1.3.4 Mexico Radiopharmaceutical Theranostics Market, by Radioisotope, 2019-2028 (US$ Million)
        • 13.1.1.3.5 Mexico Radiopharmaceutical Theranostics Market, by Source, 2019-2028 (US$ Million)
        • 13.1.1.3.6 Mexico Radiopharmaceutical Theranostics Market, by Application, 2019-2028 (US$ Million)
        • 13.1.1.3.7 Mexico Radiopharmaceutical Theranostics Market, by Indication, 2019-2028 (US$ Million)
        • 13.1.1.3.8 Mexico Radiopharmaceutical Theranostics Market, by End User, 2019-2028 (US$ Million)

14. Radiopharmaceutical Theranostics Market - Industry Landscape

  • 14.1 Overview
  • 14.2 Growth Strategies in the Radiopharmaceutical Theranostics Market
  • 14.3 Inorganic Growth Strategies
    • 14.3.1 Overview
  • 14.4 Organic Growth Strategies
    • 14.4.1 Overview

15. Company Profiles

  • 15.1 Bayer AG
    • 15.1.1 Key Facts
    • 15.1.2 Business Description
    • 15.1.3 Products and Services
    • 15.1.4 Financial Overview
    • 15.1.5 SWOT Analysis
    • 15.1.6 Key Developments
  • 15.2 GE HealthCare Technologies Inc
    • 15.2.1 Key Facts
    • 15.2.2 Business Description
    • 15.2.3 Products and Services
    • 15.2.4 Financial Overview
    • 15.2.5 SWOT Analysis
    • 15.2.6 Key Developments
  • 15.3 Curium
    • 15.3.1 Key Facts
    • 15.3.2 Business Description
    • 15.3.3 Products and Services
    • 15.3.4 Financial Overview
    • 15.3.5 SWOT Analysis
    • 15.3.6 Key Developments
  • 15.4 Lantheus Medical Imaging, Inc.
    • 15.4.1 Key Facts
    • 15.4.2 Business Description
    • 15.4.3 Products and Services
    • 15.4.4 Financial Overview
    • 15.4.5 SWOT Analysis
    • 15.4.6 Key Developments
  • 15.5 Telix Pharmaceuticals Ltd.
    • 15.5.1 Key Facts
    • 15.5.2 Business Description
    • 15.5.3 Products and Services
    • 15.5.4 Financial Overview
    • 15.5.5 SWOT Analysis
    • 15.5.6 Key Developments
  • 15.6 Cardinal Health Inc
    • 15.6.1 Key Facts
    • 15.6.2 Business Description
    • 15.6.3 Products and Services
    • 15.6.4 Financial Overview
    • 15.6.5 SWOT Analysis
    • 15.6.6 Key Developments
  • 15.7 Advanced Accelerator Applications S.A.
    • 15.7.1 Key Facts
    • 15.7.2 Business Description
    • 15.7.3 Products and Services
    • 15.7.4 Financial Overview
    • 15.7.5 SWOT Analysis
    • 15.7.6 Key Developments
  • 15.8 Jubilant Radiopharma
    • 15.8.1 Key Facts
    • 15.8.2 Business Description
    • 15.8.3 Products and Services
    • 15.8.4 Financial Overview
    • 15.8.5 SWOT Analysis
    • 15.8.6 Key Developments
  • 15.9 Theragnostics
    • 15.9.1 Key Facts
    • 15.9.2 Business Description
    • 15.9.3 Products and Services
    • 15.9.4 Financial Overview
    • 15.9.5 SWOT Analysis
    • 15.9.6 Key Developments
  • 15.10 NuView Life Sciences
    • 15.10.1 Key Facts
    • 15.10.2 Business Description
    • 15.10.3 Products and Services
    • 15.10.4 Financial Overview
    • 15.10.5 SWOT Analysis
    • 15.10.6 Key Developments

16. Appendix

  • 16.1 About The Insight Partners
  • 16.2 Glossary of Terms